These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

82 related articles for article (PubMed ID: 9199887)

  • 1. Generation of a polyclonal antibody against lipid peroxide-modified proteins.
    Kim JG; Sabbagh F; Santanam N; Wilcox JN; Medford RM; Parthasarathy S
    Free Radic Biol Med; 1997; 23(2):251-9. PubMed ID: 9199887
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Demonstration of the presence of lipid peroxide-modified proteins in human atherosclerotic lesions using a novel lipid peroxide-modified anti-peptide antibody.
    Kim JG; Taylor WR; Parthasarathy S
    Atherosclerosis; 1999 Apr; 143(2):335-40. PubMed ID: 10217362
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characterization of a specific polyclonal antibody against 13-hydroperoxyoctadecadienoic acid-modified protein: formation of lipid hydroperoxide-modified apoB-100 in oxidized LDL.
    Kato Y; Makino Y; Osawa T
    J Lipid Res; 1997 Jul; 38(7):1334-46. PubMed ID: 9254060
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A monoclonal antibody against oxidized lipoprotein recognizes foam cells in atherosclerotic lesions. Complex formation of oxidized phosphatidylcholines and polypeptides.
    Itabe H; Takeshima E; Iwasaki H; Kimura J; Yoshida Y; Imanaka T; Takano T
    J Biol Chem; 1994 May; 269(21):15274-9. PubMed ID: 8195164
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Presence of hypochlorite-modified proteins in human atherosclerotic lesions.
    Hazell LJ; Arnold L; Flowers D; Waeg G; Malle E; Stocker R
    J Clin Invest; 1996 Mar; 97(6):1535-44. PubMed ID: 8617887
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunohistochemical localization of different epitopes of advanced glycation end products in human atherosclerotic lesions.
    Sakata N; Imanaga Y; Meng J; Tachikawa Y; Takebayashi S; Nagai R; Horiuchi S; Itabe H; Takano T
    Atherosclerosis; 1998 Nov; 141(1):61-75. PubMed ID: 9863539
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Direct evidence for a protein recognized by a monoclonal antibody against oxidatively modified LDL in atherosclerotic lesions from a Watanabe heritable hyperlipidemic rabbit.
    Boyd HC; Gown AM; Wolfbauer G; Chait A
    Am J Pathol; 1989 Nov; 135(5):815-25. PubMed ID: 2683796
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunologic detection and measurement of hypochlorite-modified LDL with specific monoclonal antibodies.
    Malle E; Hazell L; Stocker R; Sattler W; Esterbauer H; Waeg G
    Arterioscler Thromb Vasc Biol; 1995 Jul; 15(7):982-9. PubMed ID: 7541296
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Macrophage-derived foam cells freshly isolated from rabbit atherosclerotic lesions degrade modified lipoproteins, promote oxidation of low-density lipoproteins, and contain oxidation-specific lipid-protein adducts.
    Rosenfeld ME; Khoo JC; Miller E; Parthasarathy S; Palinski W; Witztum JL
    J Clin Invest; 1991 Jan; 87(1):90-9. PubMed ID: 1985115
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunohistochemical evidence for the myeloperoxidase/H2O2/halide system in human atherosclerotic lesions: colocalization of myeloperoxidase and hypochlorite-modified proteins.
    Malle E; Waeg G; Schreiber R; Gröne EF; Sattler W; Gröne HJ
    Eur J Biochem; 2000 Jul; 267(14):4495-503. PubMed ID: 10880973
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Detection of oxidized phospholipid-protein adducts using anti-15-hydroperoxyeicosatetraenoic acid-modified protein antibody: contribution of esterified fatty acid-protein adduct to oxidative modification of LDL.
    Kato Y; Osawa T
    Arch Biochem Biophys; 1998 Mar; 351(1):106-14. PubMed ID: 9500842
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunochemical detection of a novel lysine adduct using an antibody to linoleic acid hydroperoxide-modified protein.
    Kawai Y; Kato Y; Fujii H; Makino Y; Mori Y; Naito M; Osawa T
    J Lipid Res; 2003 Jun; 44(6):1124-31. PubMed ID: 12700336
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Modification of delipidated apoprotein B of low density lipoprotein by lipid oxidation products in relation to macrophage scavenger receptor binding.
    Alaiz M; Beppu M; Ohishi K; Kikugawa K
    Biol Pharm Bull; 1994 Jan; 17(1):51-7. PubMed ID: 8148817
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Proanthocyanidin-rich extract from grape seeds attenuates the development of aortic atherosclerosis in cholesterol-fed rabbits.
    Yamakoshi J; Kataoka S; Koga T; Ariga T
    Atherosclerosis; 1999 Jan; 142(1):139-49. PubMed ID: 9920515
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Detection of lipofuscin-like fluorophore in oxidized human low-density lipoprotein. 4-hydroxy-2-nonenal as a potential source of fluorescent chromophore.
    Itakura K; Oya-Ito T; Osawa T; Yamada S; Toyokuni S; Shibata N; Kobayashi M; Uchida K
    FEBS Lett; 2000 May; 473(2):249-53. PubMed ID: 10812084
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Monoclonal antibody against protein-bound glutathione: use of glutathione conjugate of acrolein-modified proteins as an immunogen.
    Furuhata A; Honda K; Shibata T; Chikazawa M; Kawai Y; Shibata N; Uchida K
    Chem Res Toxicol; 2012 Jul; 25(7):1393-401. PubMed ID: 22716076
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Presence of autoantibodies against oxidatively modified low-density lipoprotein in essential hypertension: a biochemical signature of an enhanced in vivo low-density lipoprotein oxidation.
    Maggi E; Marchesi E; Ravetta V; Martignoni A; Finardi G; Bellomo G
    J Hypertens; 1995 Jan; 13(1):129-38. PubMed ID: 7759843
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Maillard reaction-like lysine modification by a lipid peroxidation product: immunochemical detection of protein-bound 2-hydroxyheptanal in vivo.
    Itakura K; Furuhata A; Shibata N; Kobayashi M; Uchida K
    Biochem Biophys Res Commun; 2003 Aug; 308(3):452-7. PubMed ID: 12914770
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oxidation-specific epitopes in human coronary atherosclerosis are not limited to oxidized low-density lipoprotein.
    O'Brien KD; Alpers CE; Hokanson JE; Wang S; Chait A
    Circulation; 1996 Sep; 94(6):1216-25. PubMed ID: 8822972
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Human serum paraoxonase (PON 1) is inactivated by oxidized low density lipoprotein and preserved by antioxidants.
    Aviram M; Rosenblat M; Billecke S; Erogul J; Sorenson R; Bisgaier CL; Newton RS; La Du B
    Free Radic Biol Med; 1999 Apr; 26(7-8):892-904. PubMed ID: 10232833
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.